Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in the Nordic Countries, Denmark, Finland, Iceland, Norway and Sweden, or involving organisations from these countries.

Total search results: 1074 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
BioGeneration Ventures–Industriens Pension: investment, 202101 final closing of BGV IV totalling €140m incl investor Industriens Pension 2021-01-07
BioGeneration Ventures–Novo Group: investment, 202101 final closing of BGV IV totalling €140m incl investor Novo Ventures 2021-01-07
BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al 2021-01-07
Faron Pharmaceuticals–Precision Medicine Group: public relations, 202101 service existent IR by Stern IR 2021-01-04
Immunicum–Van Herk: investment, 202012c largest shareholder holding 43% after merger of Immunicum with DCprime 2020-12-31
Hemab–Genmab: antibody technology, 202012 existent license to DuoBody platform to develop antibodies for bleeding disorders 2020-12-14
Hemab–Novo Group: antibody technology, 202012 existent license to IP to develop antibodies for bleeding disorders from Novo Nordisk AS 2020-12-14
Hemab–Novo Group: investment, 202012 seed investor Novo Seeds 2020-12-14
BioInnovation Institute–Novo Group: grant, 202012–203012 up to €470m funding over ten years to BBI from Novo Nordisk Foundation 2020-12-08
Single Technologies–SEVERAL: investment, 202012 financing round €5m oversubscribed share issue with existing + new investors 2020-12-04
Enduro Genetics–BioInnovation Institute: credit, 202012 pre-seed loan €470k from BII 2020-12-02
Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED 2020-12-01
SynOx Therapeutics–Odlander Fredrikson: investment, 202011 financing round Series A totalling €37m incl co-lead investor HealthCap 2020-11-19
SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv 2020-11-19
BioInvent–Van Herk: investment, 202011 existent Van Herk is largest shareholder of BioInvent 2020-11-18
DCprime–Immunicum: investment, 202011– merger with former Immunicum shareholders holding 56% + Van Herk holding 43% of combined company ANNOUNCED 2020-11-18
Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV 2020-11-12
Emisphere–Novo Group: investment, 202011– acquisition of Emisphere by Novo Nordisk for $1.35b in cash on a cash/debt-free basis 2020-11-06
The Protein Brewery–SEVERAL: investment, 202011 financing round Series A €22m led by Novo Holdings 2020-11-03
Monocl–Definitive Healthcare: investment, 202010 acquisition of Monocl by Definitive Healthcare LLC 2020-10-29
Galecto–LifeSci: public relations, 202010 supply service existent media contact LifeSci Advisors 2020-10-28
Galecto–SEVERAL: investment, 202010 US IPO $85m+12.75m with 5.67m+850k common stock shares at $15/share 2020-10-28
Kaffe Bueno–Denmark (govt): investment, 202010 seed financing round totalling €1.1m incl investor Vaekstfonden 2020-10-27
Kaffe Bueno–OTHER: investment, 202010 seed financing round totalling €1.1m incl a Danish business angel as investor 2020-10-27
Kaffe Bueno–Paulig Group: investment, 202010 seed financing round totalling €1.1m incl investor PINC 2020-10-27
Kaffe Bueno–SEVERAL: investment, 202010 seed financing round €1.1m from PINC + Vaekstfonden + The Yield Lab + a Danish business angel 2020-10-27
Kaffe Bueno–Yield Lab: investment, 202010 seed financing round totalling €1.1m incl investor The Yield Lab IE 2020-10-27
Prokarium–Flerie Invest: investment, 202010 financing round Series B totalling $21m incl co-investor Flerie Invest (FF) 2020-10-27
Prokarium–SEVERAL: investment, 202010 financing round Series B $21m led by Korea Investment Partners 2020-10-27
Oncopeptides–EU (govt): credit, 202010– unsecured €40m loan facility in three tranches with each 5y maturity from EIB 2020-10-14
Rappta Therapeutics–Advent Venture Partners: investment, 202010 financing round Series A totalling €9m incl co-investor Advent Life Sciences 2020-10-13
Rappta Therapeutics–Novartis: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novartis Venture Fund 2020-10-13
Rappta Therapeutics–Novo Group: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novo Seeds 2020-10-13
Rappta Therapeutics–Optimum Strategic Communications: public relations, 202010 service existent by Optimum 2020-10-13
Rappta Therapeutics–OTHER: investment, 202010 financing round Series A totalling €9m incl a family office as co-investor 2020-10-13
Rappta Therapeutics–SEVERAL: investment, 202010 financing round Series A €9m co-led by NVF + Novo Seeds 2020-10-13
Priothera–Odlander Fredrikson: investment, 202010 financing round Series A totalling €30m incl co-lead investor HealthCap 2020-10-12
Priothera–SEVERAL: investment, 202010 financing round Series A €30m led by Fountain Healthcare Partners 2020-10-12
Rare Thyroid Therapeutics–PledPharma: investment, 202010–202011 acquisition of RTT for SEK60m + 63.77m new shares + milestones 2020-10-05
Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Ventures 2020-09-25
Jennewein Biotechnologie–Chr. Hansen: investment, 202009– acquisition €310m on debt-free basis ANNOUNCED 2020-09-22
Sundew–Novo Group: investment, 202009 seed financing round totalling €1.4m inkl DKK10m (€1.34m) from Novo Nordisk BII 2020-09-22
Sundew–SEVERAL: investment, 202009 seed financing round €1.4m with €1.34m from Novo Nordisk BII + €85k from StartLife 2020-09-22
Sundew–StartLife (NL): investment, 202009 seed financing round totalling €1.4m inkl €85k from StartLife 2020-09-22
Lava Therapeutics–Novo Group: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Novo Ventures 2020-09-17
Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures 2020-09-17
Umotif–SEVERAL: investment, 202009 financing round Series A £5m led by existing investor AlbionVC 2020-09-03
Cartana–10x Genomics: investment, 202008 acquisition of Cartana AB by 10x Genomics Inc 2020-08-31
Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares 2020-08-19
Genkyotex–Calliditas Therapeutics: investment, 202008– acquisition in two steps for €32.3m in cash + €55m milestones (contingent rights) ANNOUNCED 2020-08-13
F2G Ltd–Novo Group: investment, 202008 financing round totalling $60.8m incl exisiting investor Novo Ventures 2020-08-12
F2G Ltd–SEVERAL: investment, 202008 financing round $60.8m from new investor Cowen Healthcare Investments + existing investors 2020-08-12
Oasmia–Consilium: public relations, 202008 service existent by CSC 2020-08-10
Reapplix–Denmark (govt): investment, 202007 financing round totalling DKK150m ($22.6m) incl existing investor Vaekstfonden 2020-07-14
Reapplix–Lauxera Capital: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor Lauxera Capital Partners 2020-07-14
Reapplix–MK Ventures: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor MK Ventures 2020-07-14
Reapplix–North East Health Care: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor North East Health Care 2020-07-14
Reapplix–Novo Group: investment, 202007 financing round totalling DKK150m ($22.6m) incl existing investor Novo Holdings 2020-07-14
Reapplix–PERSON: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor Bo Jesper Hansen 2020-07-14
Reapplix–PERSON: investment, 202007 financing round totalling DKK150m ($22.6m) incl new investor Jan Struve 2020-07-14
Reapplix–SEVERAL: investment, 202007 financing round DKK150m ($22.6m) from new + existing investors 2020-07-14
Eir Ventures–Denmark (govt): investment, 202007 first closing totalling €76m incl investor Vaekstfonden 2020-07-10
Eir Ventures–EU (govt): investment, 202007 first closing totalling €76m incl investor EIF 2020-07-10
Eir Ventures–Novo Group: investment, 202007 first closing totalling €76m incl investor Novo Holdings 2020-07-10
Eir Ventures–Optimum Strategic Communications: public relations, 202007 service existent by Optimum 2020-07-10
Eir Ventures–SEVERAL: investment, 202007 first closing €76m from Saminvest + EIF + Vaekstfonden + Novo Holdings + private investors 2020-07-10
Eir Ventures–Sweden (govt): investment, 202007 first closing totalling €76m incl investor Saminvest 2020-07-10
VarmX–SEVERAL: investment, 202007 financing round Series B €32m co-led by Ysios Capital + INKEF Capital 2020-07-08
Resistell–EU (govt): grant, 202007 up to €2.5m grant + equity financing offer from EIC programme/fund 2020-07-03
Freeline Therapeutics–Novo Group: investment, 202006 financing round Series C final closing totalling $80m incl co-lead investor Novo Holdings A/S 2020-06-30
Freeline Therapeutics–SEVERAL: investment, 202006 financing round Series C final closing $80m (£61.2m) co-led by Novo Holdings + Eventide + Wellington 2020-06-30
JnJ–Bavarian Nordic: vaccine, 202006– supply $13.9m manufacturing + delivery of MVA-BN Filo Ebola vaccine to Janssen Vaccines & Prevention BV 2020-06-12
Corvidia Therapeutics–Goodwin Procter: legal services, 202006 supply service legal advisor to Cordivia for acquisition by Novo Nordisk 2020-06-11
Corvidia Therapeutics–JPMorgan Chase: financial services, 202006 supply service advisor to Cordivia for acquisition by Novo Nordisk 2020-06-11
Corvidia Therapeutics–Novo Group: investment, 202006 acquisition $725m upfront cash + $1.375b milestones cash by Novo Nordisk ANNOUNCED 2020-06-11
Novo Group–Davis Polk & Wardell: legal services, 202006 supply service legal advisor to Novo Nordisk for acquisition of Corvidia Therapeutics 2020-06-11
Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab 2020-06-10
Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al 2020-06-10
Valo Therapeutics–Scius Communications: public relations, 202006 supply service existent by Scius Communications 2020-06-08
NodThera–Novo Group: investment, 202006 financing round Series B totalling £44m ($55m) incl lead investor Novo Ventures 2020-06-03
NodThera–SEVERAL: investment, 202006 financing round Series B £44m ($55m) led by Novo Ventures 2020-06-03
Genmab–Rentschler: biologics contract manufacturing, 202005– collab expansion production of DuoBody products to new Rentschler US facility 2020-05-27
Exscientia–SEVERAL: investment, 202005 financing round Series C $60m led by Novo Holdings + incl Evotec + BMS + GT Healthcare Capital 2020-05-26
Kaiku Health–Elekta: investment, 202005 acquisition 100% of Kaiku Health by Elekta 2020-05-15
Calliditas Therapeutics–SEVERAL: investment, 202005–202006 private placement SEK82.9m with 924k common shares at SEK89.7/share outside US 2020-05-14
Calliditas Therapeutics–SEVERAL: investment, 202005–202007 US IPO $81m+$6.9m with w 8.3m+707k common shares as ADSs at Nasdaq Global Market 2020-05-14
Oncopeptides–SEVERAL: investment, 202005 directed share issue SEK1.414b ($144m) with 12.295m new shares at SEK115/share 2020-05-05
EnginZyme–SEVERAL: investment, 202004 financing round Series A €6.4m led by Sofinnova Partners 2020-04-22
EnginZyme–Sofinnova: investment, 202004 financing round Series A totalling €6.4m incl lead investor Sofinnova Industrial Biotech Fund 2020-04-22
Leo Pharma–Oneness Biotech: therapeutic antibody, 202004– license ww excl to FB825 $40m upfront + $530m milestones + royalties from Oneness + MBS 2020-04-15
Servier–Gorrissen Federspiel: legal services, 202004 supply service Gorrissen Federspiel legal advisor to Servier w regard to acquisition of Symphogen 2020-04-03
Servier–Lazard: financial services, 202004 supply service Lazard financial advisor to Servier w regard to acquisition of Symphogen 2020-04-03
Servier–McDermott Will & Emery: legal services, 202004 supply service MWE legal advisor to Servier w regard to acquisition of Symphogen 2020-04-03
Symphogen–Perkins Coie: legal services, 202004 supply service Perkins Coie legal advisor to Symphogen w regard to acquisition by Servier 2020-04-03
Symphogen–Plesner: legal services, 202004 supply service Plesner AP legal advisor to Symphogen w regard to acquisition by Servier 2020-04-03
Symphogen–Rothschild & Co: financial services, 202004 supply service Rothschild & Co financial advisor to Symphogen w regard to acquisition by Servier 2020-04-03
Symphogen–Servier: investment, 202004–202006 acquisition 100% €na 2020-04-03
Gilde Investment–SEVERAL: investment, 202003 first + final close of €416m Gilde Healthcare V fund incl investors Philips + Rabo Corp Investments 2020-03-31
Obi Medical–Roche: investment, 202003 acquisition of Obi Medical ApS by Roche 2020-03-31
Tempus Labs–Novo Group: investment, 202003 financing round Series G totalling $100m incl investor Novo Holdings 2020-03-13
1 2 3 4 5 6 7 8 9 10 11  next pagenext page



Advertisement

Picture ConsulTech GmbH RnD Credit Germany 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top